White Paper | Optimizing Backfilling Strategies for Phase I Oncology Studies

In early development, if safety is not an issue, the optimal dose is the dose that is the most effective. Response rate is generally the preferred criteria. However, how can we determine the best dose with small sample sizes? The main dilemma is to deliver far too large dose as long as safety do not stop the escalation.

This site uses cookies to personalize and customize your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Secured By miniOrange